A new analysis, designed to shed light on the benefits of SGLT2 inhibition in patients who have heart failure with preserved ejection fraction (HFpEF), shows that dapagliflozin (Farxiga; AstraZeneca) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback